[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryopreservation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryopreservation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100580268","cryopreservation-of-ovarian-tissue-reimplantation-rate-and-effects-on-ovarian-function-100580268",false,"NCT06835088","Cryopreservation of Ovarian Tissue: Reimplantation Rate and Effects on Ovarian Function","Cryopreservation Of Ovarian Tissue: Assessment Of Reimplantation Rate And Effects On Ovarian Function","Inclusion Criteria:\n\n* Age: 13-55 years\n* Suffering from diseases that require gonadotropic treatments\n* Have been subjected to sampling and cryopreservation of ovarian tissue at the Operative Unit of Gynecology and Pathophysiology of Human Reproduction of the Sant'Orsola Polyclinic in Bologna\n* Informed Consent Acquisition\n\nExclusion Criteria:\n\n\\- Oncological pathology still active or relapse","FEMALE","13 Years","55 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Premature ovarian failure (POI) is a clinical syndrome defined by the loss of ovarian activity before age 40. POI is characterized by amenorrhea or oligomenorrhea with elevated gonadotropins, low estradiol and serious consequences on fertility.\n\nThe prevalence of POI in the general population is about 1%. In recent years, the incidence of iatrogenic POI in cancer women is increasing: 4% of patients of fertile age are diagnosed with neoplasms and gonadal treatments that can sterilize them, such as chemotherapy and radiotherapy. Preserving fertility is a key objective for many cancer patients.\n\nBefore gonadotoxic treatments, patients in the post-pubertal age with future desire for pregnancy may opt for two main methods of preservation of fertility (FP): egg cryopreservation (OC) after ovarian stimulation and cryopreservation of ovarian tissue (OTC). An important limitation of the latter technique is the reduced number of patients who return to use the cryopreserved material, leading to a negative impact on the evaluation of the effectiveness of the procedure. The best way to maximise the effectiveness of the procedure in clinical and economic terms would be to increase the number of patients who continue the cryopreservation path by completing it with subsequent reimplantation. It would also be useful to improve the follow-up of these patients by evaluating their ovarian function over time, before and after the removal and reimplantation, through the study of bone metabolism, cardiovascular risk and psychological function in these women.",[25],"Cryopreservation",[27,28,29],"cryopreservation","ovarian tissue","ovarian function","RECRUITING","2025-02-14",{"date":33,"type":34},"2025-02-19","ACTUAL",{"date":36,"type":34},"2021-09-12",{"date":38,"type":21},"2031-12-30",{"name":40,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls",true,"18 Years","50 Years",{"count":55,"type":21},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[59,60,61,62,63,25,64,65],"Childhood Cancer Survivors","Fertility","Ovarian Reserve","CED","Ovarian Reserve Markers","Alkylating Agents","Female","2024-10-30",{"date":68,"type":34},"2024-11-01",{"date":70,"type":34},"2024-10-09",{"date":72,"type":21},"2028-12-31",{"name":74,"class":41},"Centre Hospitalier Universitaire de Liege",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":42},"100536194","improving-the-quality-of-cryopreserved-ovarian-tissue-reimplantation-using-platelet-enriched-autologous-plasma-100536194","NCT06261658","Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma","TESOVA2022","Inclusion Criteria:\n\n* request for cryopreserved ovarian tissue transplantation;\n* premature ovarian failure or irregular mentrual cycles;\n* negative test for HIV, HBV, HCV, Treponema pallidum;\n* negative PAP test;\n* oncological authorization;\n* absence of neoplastic contamination in the cryopreserved ovarian tissue;\n* Informed consent\n\nExclusion Criteria:\n\n* neoplastic contamination in cryopreserved ovarian tissue;\n* history of endometriosis;\n* endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);\n* body mass index (BMI) \\>30 kg\u002Fm2;\n* circulating platelet level \\\u003C 150,000 \u002F mml;\n* bacterial infection;\n* ongoing use of anticoagulants;\n* bleeding diathesis.",{"count":83,"type":21},45,"INTERVENTIONAL",[86],"NA","The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.",[25,89,90,91],"Ovary Injury","Infertility, Female","Menopause Ovarian Failure",[93,94,95,96,97],"Cryopreserved Ovarian Tissue","Ovarian tissue transplantation","Platelet-enriched Autologous Plasma","ovarian endocrine function","livebirths","2024-02-08",{"date":100,"type":34},"2024-02-15",{"date":102,"type":21},"2024-03-01",{"date":104,"type":21},"2033-12-29",{"name":40,"class":41}]